Objective: The objective of the present study was to compare the efficacy of two forms of menopausal hormone therapy in alleviating vasomotor symptoms, insomnia, and irritability in early postmenopausal women during 4 years.
M enopausal symptoms are experienced by a majority of women. 1 Although women in the perimenopause age range of 40 to 55 report many different types of symptoms, not all are necessarily linked to ovarian senescence and the loss of estradiol (E 2 ) and progesterone production. It remains challenging to disentangle age-related symptoms from those attributable to, or interacting with, menopause. 1 Vasomotor symptoms (VMSs), or hot flashes and sweats, are in many ways the quintessential menopausal symptom. Up to 85% of women report onset or significant increases in VMS at menopause. 2, 3 There is little disagreement about the linkage of VMS to ovarian hormone, and, particularly, estrogen, production. Menopausal hormone therapy (HT) is highly effective for the treatment of hot flashes. 4, 5 HT treatment is most commonly given for just a few years flanking the final menstrual period, although some women with prolonged symptoms require longer courses of therapy. In particular, recent studies indicate that hot flashes may persist for 10 years or more after the final menstrual period. 6 Although nonhormonal prescription drugs are known to have modest effectiveness against VMS, they remain inferior to estrogen in the magnitude of benefit, 7, 8 and there is only one Food and Drug Administration-approved alternative to estrogen for the treatment of hot flashes (paroxetine mesylate). 9 Fewer studies have examined the role of hormones in the treatment of the less prevalent menopausal symptoms such as depressed mood 10, 11 and disturbed sleep, 12 and fewer still have compared HT regimens, especially during extended durations, to determine which are most effective for particular outcomes or symptoms. 13, 14 The Kronos Early Estrogen Prevention Study (KEEPS) was a multicenter clinical trial designed to compare effects of lowdose oral conjugated estrogens (o-CEE) with those of transdermal estradiol (t-E 2 ) versus placebo (PBO) on cardiovascular endpoints in recently postmenopausal women. 15 Herein, we report a comparison of self-reported symptoms over time in KEEPS participants randomized to o-CEE, t-E 2 , or PBO in whom the prevalence of vasomotor, mood, and sleep symptoms was assessed and the presence and severity of symptoms were compared across treatments during 4 years of trial duration. We hypothesized that menopausal symptoms would be prevalent in the KEEPS cohort at baseline, that both hormone regimens would be more effective in alleviating symptoms compared with PBO, and that symptoms would subside over time in all groups. We also hypothesized that baseline demographics and anthropometric measures would influence prevalence and severity of symptoms at baseline and their response to treatment.
METHODS
KEEPS enrolled 727 women aged 42 to 58 years who were at least 6 months but less than 36 months from their last menses with a follicle-stimulating hormone level at least 35 mIU/mL and/or E 2 less than 40 pg/mL. Age at menopause was determined at phone screening and verified at the baseline visit. Women were randomized to either o-CEE 0.45 mg daily (n ¼ 230) or t-E 2 50 mg daily (n ¼ 225), both with oral micronized progesterone 200 mg daily for 12 days each month and both with a PBO for the treatment not given versus a control arm receiving triple PBO (patch and pills) group (n ¼ 275). Nine recruitment sites from across the USA participated in the KEEPS trial (ClinicalTrials.gov; trial number NCT00154180). Details on the enrolled population have been reported. 15 All women had a benign Pap smear and a normal mammogram within 1 year before randomization. Past or current users of HT were screened only after at least a 90-day washout period. Women with a history of clinical cardiovascular disease, including myocardial infarction, angina, congestive heart failure, stroke, transient ischemic attacks, or thromboembolic disease, were excluded, as were those who reported smoking more than 10 cigarettes per day. All women meeting initial eligibility criteria had a complete blood count and chemistry panel measured at the clinical laboratories at each study center. Lipid profiles and thyroid-stimulating hormone were measured at the Kronos Science Laboratories (Phoenix, AZ). Women were also screened for coronary artery calcium, and those with scores at least 50 AU were excluded.
A planned secondary analysis of the KEEPS included a central evaluation of circulating estrone (E 1 ) and E 2 in a subset of participants at baseline and on treatment to determine compliance with the treatment regimen 16 and to assess the relationship of circulating hormone levels on symptom relief. For these analyses, E 1 and E 2 were measured on a randomly selected subsample of women from all three treatment arms by the Reproductive Endocrine Research Laboratory of the USC Keck School of Medicine (Los Angeles, CA) using a highly sensitive, well-validated radioimmunometric method after extraction of 0.8 mL of serum with ethyl acetate/ hexane (3:2) followed by Celite column partition chromatography. 17, 18 Recovery of tritiated E 2 (range 73%-86%) was used to correct observed values. The limit of detection for E 2 was 2 pg/mL. Inter-and intra-assay coefficients of variation for E 2 were 6% and 4%, respectively.
Short follow-up visits were scheduled every 90 days (in person or by phone with medications mailed) to assess adverse events and adherence (pill/patch counts). Longer in-person visits were conducted at 12, 18, 36, and 48 months to measure cardiovascular or cognitive endpoints.
All participants completed a menopausal symptom checklist before randomization and again at 6, 12, 24, 36, and 48 months. Menopausal symptoms included in the present analysis were self-assessed and included only current symptoms: hot flashes, night sweats, insomnia, and irritability. Symptoms were scored on a 4-point ordinal scale: 0 (no symptoms) to 1 (mild), 2 (moderate), and 3 (severe). ''Symptomatic'' for each menopausal symptom was dichotomously defined as moderate/severe (vs none/mild) for most analyses; for the comparison of symptom severity to circulating E 2 , four-category symptom severity score was used (see below).
History of tobacco use was captured based on a combination of a screening question, which screened out women who smoked more than 10 cigarettes/d, and a Tobacco Use Form designed to capture lifetime pack-years of smoking, introduced at the study's midpoint. Diet and physical activity were assessed at the first clinic screening visit. 19 Additional validated instruments were administered to assess mood 20, 21 and cognition 22 ; a standardized, comprehensive cognitive test battery was also performed as a substudy to the KEEPS called the KEEPS Cognitive and Affective Study (KEEPS-Cog); these results have been reported. 23, 24 Physical measures (height, weight, waist and hip circumference, blood pressure) were obtained at all visits using standardized protocols. 15 Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters, squared). BMI was categorized using international classification definitions: 30 being obese, 25 to less than 30 being overweight, and less than 25 being normal (or possibly underweight). Race/ethnicity was self-reported. Analysis of genetic polymorphisms in the KEEPS sample confirmed women's self-reports in that the majority of participants were of white, Central European ancestry. 25 
Data management
Data were entered at study centers into secure online forms in Practical Extraction and Report Language and transferred to the database management system at the KRONOS Coordinating Center. Data were subsequently uploaded for analysis and converted to SAS datasets at the UCSF data coordinating center.
Data analysis
Data were analyzed based on original treatment assignment (intent to treat). All reported results are from the intent-totreat analysis. Available data were used without imputation for missing values in the primary analysis.
Comparisons of baseline characteristics across the three treatment groups are reported as frequency and percent for categorical, or mean (SD) for continuous variables, with P values from x 2 (exact where possible), or analysis of variance, comparing across all three groups. In a logistic model of each symptom at baseline, three-category BMI and three-category race/ethnicity were included as covariates to compare overall symptom prevalence by race/ethnicity and BMI. Racial and ethnic groups compared included white, black, and other (composed of women reporting Asian, Hispanic, or any other ethnicity that could not be considered either white or black). Comparisons of symptoms by race and BMI are reported as odds ratios (ORs) and 95% CIs.
The percentage of women who were symptomatic at screening and at each follow-up time point was assessed. To test if either hormone regimen was more effective than PBO in alleviating symptoms, the proportion of women who were symptomatic (reported moderate/severe symptoms) at each follow-up visit was summarized by treatment, with comparisons tested using logistic regression between each of the treated groups versus PBO, and also between treatment groups (as an exploratory analysis).
In a secondary analysis, symptoms over time were modeled using two general linear mixed effects models for the logistic distribution with an interaction between (1) treatment arm and (2) three-category race/ethnicity, and separately threecategory BMI.
The relationship between severity of VMSs and circulating E 2 concentrations was compared across four-category VMSs at baseline (reflecting the relationship between endogenous E 2 and VMS) and 12 months (reflecting the relationship between t-E 2 and VMS), with differences tested using analysis of variance and pairwise comparisons within a general linear model. Because the E 2 distribution was rightskewed, data were log-transformed for analysis and backtransformed for reporting of geometric mean concentrations with 95% CI. The linear relationship of log-scale E 2 at month 12 was compared within a general linear model by testing differences across treatment group in slope of E 2 .
As a sensitivity analysis, all women with missing symptom data were assigned the worst symptomatic category, and all analyses were performed again. A second sensitivity analysis was performed to examine whether a different cut point for symptoms (any vs none) changed the results.
A P < 0.05 was used to determine statistical significance. SAS 9.4 was used to carry out the statistical analysis, and graphics were created using GraphPad Prism 6.
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RESULTS
Recruitment and flow of participants through the study have been previously reported and are shown in Supplemental Figure 1 (Supplemental Digital Content 1, 16 http://links. lww.com/MENO/A191). Owing to study dropout, there were fewer women available to report symptoms at each successive time point. Participant attrition from screening to 48 months was similar in all groups such that 173 of 230 (75.2%) women randomized to o-CEE, 170 of 222 (76.6%) women randomized to t-E 2 , and 211 of 275 (76.7%) women randomized to PBO completed the endof-study assessment (Fig. 1) . Baseline characteristics of the KEEPS cohort and baseline symptom reporting of moderate to severe symptoms by randomization assignment are shown in Table 1 .
Vasomotor symptoms: hot flashes/night sweats Unadjusted prevalence of hot flashes and night sweats are shown in Table 2 and Figure 2 for all time points. At screening, 86% of all participants reported at least mild hot flashes, whereas moderate to severe hot flashes were reported by 44%. By 6 months postrandomization, moderate to severe hot flashes had decreased to 28.3% of women randomized to PBO, 7.4% of women randomized to t-E 2 , and 4.2% of women randomized to o-CEE (P < 0.001 for each active treatment vs PBO). Night sweats were reported by 68% of women at screening, with 35% being moderate to severe. At 6 months, moderate to severe night sweats declined to 19% with PBO, 5.3% with t-E 2 , and 4.7% with o-CEE (P < 0.0001 for each active treatment vs PBO). This initial magnitude of symptom reduction was maintained throughout the study in all treatment groups.
Insomnia and irritability
At baseline, the proportion of women reporting insomnia did not differ between treatment groups (PBO 34%, o-CEE 29%, and t-E 2 35%, P ¼ 0.3) (Table 2; Fig. 2 ). Insomnia decreased substantially and comparably by 6 months in all groups, and this decrease was maintained throughout the trial. At 36 and 48 months, o-CEE was significantly more effective in reducing insomnia versus PBO (P ¼ 0.002 and 0.05), and at 48 months t-E 2 was more effective than PBO (P ¼ 0.004). Baseline reports of irritability were similar between treatment groups (PBO 15%, o-CEE 17%, and t-E 2 19%, P ¼ 0.6) and decreased comparably by about half in all groups at 6 months, to 7.5%, 6.9%, and 5.8%, respectively, and did not differ between treatment groups at any time point.
Differences in treatment effect by demographics
For each symptom, the relationship of race/ethnicity and BMI to treatment effect was calculated. Owing to small numbers of women for some of the time points, a fully interacted model could not be constructed for night sweats or irritability. The effects of o-CEE as well as t-E 2 versus PBO on hot flashes and insomnia showed no significant interaction by BMI or race/ethnicity.
Sensitivity analyses
Because severe symptoms might have caused differential loss of data due to selective visit avoidance or study dropout, which could result in artifactual symptom relief, we performed a sensitivity analysis, recategorizing all missing responses as being due to the presence of moderate to severe symptoms. This analysis did not, however, significantly alter any of the above treatment effects or lack thereof, compared with the above results. Changing the point at which the symptom variable was dichotomized to ''any'' versus ''none'' resulted in identical patterns of symptom relief among groups (Supplemental Fig. 2 , Supplemental Digital Content 2, http://links.lww.com/MENO/A192).
Relationship of circulating E 2 to hot flashes
Serum E 2 levels were available in a subset of 426 women at baseline (135 o-CEE, 131 t-E 2 , and 158 PBO) and 424 women at 12 months (194 o-CEE, 181 t-E 2 , and 227 PBO). E 2 concentrations at baseline did not significantly differ by symptom severity score categories for either hot flashes or night sweats. At 12 months, among women randomized to t-E 2 , circulating E 2 was, however, significantly higher among nonsymptomatic women than among women reporting moderate or severe symptoms. At 12 months, among women randomized to t-E 2 , those reporting no hot flashes had a geometric mean E 2 of 44.26 pg/mL (95% CI 38.97, 50.27), significantly higher than women reporting moderate (9.12 pg/ mL [95% CI 5.85, 14.20], P 0.001) or severe (11.04 pg/mL [95% CI 5.35, 22.77], P ¼ 0.01) hot flashes. Similar findings were observed for night sweats at month 12 (data not shown).
Screening symptoms by race/ethnicity
Before randomization, reporting of symptoms differed significantly by race/ethnicity for every symptom (P ¼ 0.03 for hot flashes, otherwise P < 0.001) in a model including [11.72, 31 .57]). Comparisons between other versus white women and other versus black women revealed progressively smaller between-group differences. In terms of absolute value, unadjusted differences at baseline were highest among black women relative to white women and women of other races for moderate to severe hot flashes (52%, 44%, 41%, respectively), night sweats (46%, 34%, 35%, respectively), and especially moderate to severe irritability (33%, 15%, 21%, respectively). Baseline insomnia was reported by similar proportions of black women (35%), white women (32%), and women of other races (36%). 
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DISCUSSION This study is the first to compare menopausal symptoms longitudinally by treatment regimen and route of administration in women taking different types of low-dose estrogen therapy in combination with oral micronized progesterone. Overall, HT with either o-CEE or t-E 2 was highly effective in relieving the more traditional menopausal symptoms of hot flashes and night sweats, with little difference in effectiveness between either of the two active treatment groups. There was pronounced reduction of moderate to severe symptoms, which typically drive women to seek treatment. Relief from symptoms with HT relative to PBO was maintained for the 48-month follow-up period for each treatment arm, despite an overall decrease in hot flashes and night sweats in the PBO group during the course of the study. The clear-cut effect observed for both active treatments is consistent with the current and most accepted indication for HT, that is, treatment of menopausal symptoms.
In contrast to favorable changes in mood with HT reported in the KEEPS-Cog study, which included detailed psychological and cognitive testing in the women in the KEEPS cohort, 23 we observed little effect of either of the two active treatments on irritability. Notably, a statistically significant treatment-related reduction in insomnia, however, emerged toward the end of the follow-up period, which was largely due to an increase in insomnia after 12 months in the women randomized to PBO. HT-related decreases in hot flashes and night sweats persisted despite decreases in these symptoms in the PBO group over time.
There are several possible explanations for the overall longitudinal decrease in VMSs with PBO. The first and most likely is that the timing of the KEEPS intervention coincides with the natural history of these menopausal symptoms, because menopausal symptoms tend to be worst within the year surrounding the final menses and then often spontaneously subside. 26 VMSs are worst within the year surrounding the final menses. 26, 27 Because KEEPS participants were all at least 6 months but no more than 3 years past their final menses (22 mo on average, similar in all three treatment arms), it is not surprising that VMSs would tend to improve over time with PBO. The very large initial decrease in both hot flashes and night sweats from screening to 6 months, however, may be beyond that from natural history alone and instead may reflect a substantial ''PBO effect'' with initiation of study treatments.
These data on the effectiveness of HT for hot flashes and night sweats are in agreement with prior clinical trials in which other doses and formulations of HT were used. Both the Women's Health Initiative (WHI) and the Heart and Estrogen/ Progestin Replacement Study (HERS) reported improvements in self-reported symptoms with HT at an o-CEE dose higher than what was administered in KEEPS. [28] [29] [30] The present report underscores the concept that both oral and transdermal HT are very effective treatments for the common menopausal symptoms of hot flashes and night sweats, with some possible effectiveness for sleep complaints as well. It is also notable that o-CEE and t-E 2 were remarkably similar in their ability to relieve symptoms. No other trials have compared these low-dose HT treatments with each other, especially during 4 years of follow-up.
The prevalence of insomnia reported by KEEPS participants and its increase over time are similar to those in 30.8%
FIG. 2.
Unadjusted cross-sectional prevalence of symptoms over time. The proportion of women reporting moderate to severe symptoms is shown at each assessment. The x axis indicates the month of study. Significant differences from PBO indicated by additional symbol: (X) P < 0.01 and (þ) 0.01 < P < 0.05. o-CEE, oral conjugated estrogens; PBO, placebo; t-E 2 , transdermal estradiol.
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of women in a comparable population of midlife women from the Study of Women's Health Across the Nation, which observed an increase in this complaint during the menopausal transition to more than 40% during the late transition and postmenopause. 31, 32 The increase of moderate to severe symptoms of insomnia in the PBO group began to appear at 12 months, and led to a statistically significant improvement in insomnia for both active treatment arms at years 3 and 4. This finding may indicate a late effect of menopause on sleep efficiency that has not been previously appreciated, but the finding should be interpreted with caution because it was toward the end of the study when fewer participants provided data for the analysis. Poor sleep of various types, including insomnia, has been attributed to be a cardinal symptom of the menopausal transition by some, 32 but not other, 33 investigators. It is possible that the timing of this symptom is later after menopause than previously believed, and its relationship to a woman's hormone status is more complex than a simple model of estrogen and progesterone withdrawal. It is also possible that the use of a nonvalidated survey to self-report insomnia lacked the sensitivity to detect between-group differences earlier in the study.
Irritability declined in all groups, regardless of whether the women were treated with HT or PBO. In a prior analysis from the KEEPS-Cog study, o-CEE reduced scores for depression and anxiety, whereas t-E 2 did not. 23 Only a single aspect of mood, irritability, was measured, and this may have been insufficiently sensitive to detect a treatment effect.
The favorable impact of HT is further underscored by the inverse correlation between circulating E 2 levels and the prevalence of hot flashes in the t-E 2 group, as well as an inverse relationship between self-reported adherence to treatments and menopausal symptoms in both active treatment arms. Lower symptom prevalence was associated with higher circulating E 2 among women randomized to t-E 2 . Women demonstrated a wide range of E 2 levels, from as low as 11 pg/ mL in women reporting severe hot flashes to as high as 44 pg/ mL in women reporting no hot flashes. It is possible that this variation is in the past due to a lack of strictly controlled timing of blood draws in relation to patch application and pill ingestion. The only other study, to our knowledge, that has examined hot flash relief in relation to circulating E 2 in women taking t-E 2 was performed more than three decades ago, used a reservoir (not a matrix) t-E 2 delivery system, and reported a therapeutic range for serum E 2 of 61 pg/mL and 122 pg/mL for a 50% and 100% (theoretical) reduction in hot flashes. 4 This study used a radioimmunoassay without a chromatographic separation step for E 2 determination, which lacks sensitivity at the low levels found in postmenopausal women. 34 Owing to chemical differences between the treatments, E 2 levels are much lower with o-CEE than with t-E 2 but instead the majority of the estrogenic effect with o-CEE is due to circulating E 1 and other B-ring equine estrogens (which were not measured). E 1 can be converted to E 2 to some degree, so effective concentrations of E 2 at the tissue level in the o-CEE group may be of clinical importance.
Despite a rigorous trial design and large study sample, limitations of this study merit consideration. Although dropout was comparable with other trials of HT, it was still substantial. This trial was not powered to assess superiority of one route of estrogen therapy over another. In addition, the frequency of menopausal symptoms was not queried, but instead only their severity. This lack of data may have obscured differences between active treatment and PBO. Also, questionnaires asked only about current symptoms, and did not require participants to recall symptoms during the prior weeks or months. Although reporting of current symptoms tends to be more valid than recall of prior symptoms, it will underestimate prevalence of symptoms that fluctuate greatly over time. KEEPS did not use lengthier, well-validated, multidimensional measures of the symptoms under study because it was necessary to balance participant burden against the information to be gained. Study of symptom relief was a planned secondary endpoint of the KEEPS. Nonetheless, the use of a subjective severity measure for hot flashes and other symptoms is validated by other clinical trials. 7, 35, 36 Given that the KEEPS population is predominantly non-Hispanic and white, and was generally healthier and better educated than the average US woman, this may influence the generalizability of the findings and limit the ability to reliably assess ethnic and racial differences in symptom relief from HT among nonwhite women. Finally, the use of multiple comparisons in this study could have led to positive findings due to chance.
In addition, using a sensitivity analysis that imputed moderate/severe symptoms in all of the participants who dropped out, the relationships observed between HT and symptom relief remained remarkably similar, making differential dropout of the most symptomatic women (who would then have presumably gone onto HT in a setting outside of the study) an unlikely explanation for these findings.
CONCLUSIONS
In summary, there was significant relief of the menopausal symptoms of hot flashes, night sweats, and self-reported insomnia for 4 years and it was comparable between o-CEE 0.45 mg daily and t-E 2 50 mg/d, combined with cyclic, oral micronized progesterone. Other symptoms, such as irritability and insomnia, were less influenced by HT.
